J Clin Oncol 20 (15): 3317-27, 2002.[PUBMED Abstract] Tevaarwerk AJ, Wang M, Zhao F, et al.: Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
J Clin Oncol 32 (35): 3948-58, 2014.[PUBMED Abstract] Francis PA, Regan MM, Fleming GF, et al.: Adjuvant ovarian suppression in premenopausal breast cancer.
N Engl J Med 372 (5): 436-46, 2015.[PUBMED Abstract] Francis PA, Pagani O, Fleming GF, et al.: Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.